Proposed revision of the 8th edition AJCC clinical staging system for esophageal squamous cell cancer treated with definitive chemo-IMRT based on CT imaging.


Journal

Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111

Informations de publication

Date de publication:
28 Mar 2019
Historique:
received: 30 12 2018
accepted: 20 03 2019
entrez: 30 3 2019
pubmed: 30 3 2019
medline: 6 8 2019
Statut: epublish

Résumé

To validate and propose revision of the 8th edition American Joint Committee on Cancer (AJCC) clinical staging system for esophageal squamous cell cancer (ESCC) patients treated with definitive intensity-modulated radiation therapy combined with concurrent chemotherapy (Chemo-IMRT) based on computed tomography (CT) imaging. The clinical data of patients with ESCC treated with Chemo-IMRT were collected and retrospectively reviewed. All CT images were independently reevaluated and restaged according to the 8th edition AJCC staging system. The overall survival (OS) rates were analyzed statistically. ROC curves of the various parameters of the primary tumor and metastatic lymph nodes were generated in order to identify the cutoff values correlated to patient survival using the area under curve. The gross tumor volume of the primary tumor (GTV-prT) and the clinical N stage (cN) were independent factors that influenced OS. The 5-year OS rate of patients with GTV-prT ≤28 cm The SLNM should be dealt with as a regional rather than a distant disease in patients with ESCC when treated with CRT. The proposed nonsurgical staging system based on the GTV-prT and N appears to be a simple and accurate prognosis predictor for patients with ESCC who have undergone definitive Chemo-IMRT.

Identifiants

pubmed: 30922343
doi: 10.1186/s13014-019-1258-4
pii: 10.1186/s13014-019-1258-4
pmc: PMC6437982
doi:

Types de publication

Journal Article

Langues

eng

Pagination

54

Subventions

Organisme : Fujian Provincial Health & Family Planning Commission
ID : 2016-ZQN-32
Organisme : Fujian Provincial Department of Science and Technology
ID : 2018J01306
Organisme : Fujian Provincial Department of Science and Technology
ID : 2018Y2003
Organisme : Fujian Provincial Department of Science and Technology
ID : 2017Y9079
Organisme : Fujian Provincial Platform for Medical Laboratory Research&Key Laboratory for Tumor Individualized Active Immunity
ID : FYKFKT- 2017015

Références

Gut. 2001 Oct;49(4):534-9
pubmed: 11559651
World J Gastroenterol. 2004 Apr 15;10(8):1098-102
pubmed: 15069706
J Clin Oncol. 2005 Jul 10;23(20):4483-9
pubmed: 16002838
World J Surg. 2005 Jun;29(6):700-7
pubmed: 16078126
J Surg Oncol. 2006 Oct 1;94(5):355-63
pubmed: 16967455
J Thorac Cardiovasc Surg. 2009 Jan;137(1):55-9
pubmed: 19154903
Ann Thorac Surg. 2011 Mar;91(3):887-93
pubmed: 21353021
Lancet. 2013 Feb 2;381(9864):400-12
pubmed: 23374478
Ups J Med Sci. 2013 Aug;118(3):145-52
pubmed: 23617771
Dis Esophagus. 2015 May-Jun;28(4):352-7
pubmed: 24635657
N Engl J Med. 2014 Dec 25;371(26):2499-509
pubmed: 25539106
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
J Gastrointest Cancer. 2015 Jun;46(2):131-7
pubmed: 25759174
Int J Surg. 2015 Aug;20:113-7
pubmed: 26118612
J Thorac Dis. 2016 Jun;8(6):1155-61
pubmed: 27293832
Jpn J Clin Oncol. 2016 Sep;46(9):805-10
pubmed: 27380810
Acta Oncol. 2017 Jan;56(1):33-38
pubmed: 27842455
Am Fam Physician. 2017 Jan 1;95(1):22-28
pubmed: 28075104
Esophagus. 2017;14(1):1-36
pubmed: 28111535
J Chin Med Assoc. 2017 Oct;80(10):636-643
pubmed: 28716602
Head Neck. 2017 Dec;39(12):2406-2415
pubmed: 28960561
Medicine (Baltimore). 2018 Jun;97(22):e10928
pubmed: 29851829
Dis Esophagus. 2018 Nov 1;31(11):null
pubmed: 29961898
Radiat Oncol. 2018 Aug 15;13(1):150
pubmed: 30111361
Radiat Oncol. 2018 Oct 16;13(1):200
pubmed: 30326912

Auteurs

Mingqiu Chen (M)

Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, No. 420, Fumalu Road, Jinan District, Fuzhou City, Fujian Province, People's Republic of China, 350014.
Fujian Provincial Platform for Medical Laboratory Research of First Affiliated Hospital, Fuzhou, Fujian, People's Republic of China.

Xiqing Li (X)

The Graduate School, Fujian Medical University, Fuzhou, Fujian, People's Republic of China.

Yuangui Chen (Y)

Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China.

Pingping Liu (P)

The Graduate School, Fujian Medical University, Fuzhou, Fujian, People's Republic of China.

Zhiwei Chen (Z)

Fuzhou Center for Disease Control and Prevention, Fuzhou, Fujian, People's Republic of China.

Minmin Shen (M)

The Graduate School, Fujian Medical University, Fuzhou, Fujian, People's Republic of China.

Xiaohong Liu (X)

The Graduate School, Fujian Medical University, Fuzhou, Fujian, People's Republic of China.

Yu Lin (Y)

Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, No. 420, Fumalu Road, Jinan District, Fuzhou City, Fujian Province, People's Republic of China, 350014.

Rongqiang Yang (R)

Cancer and Genetics Research Complex, Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL, USA.

Wei Ni (W)

Cancer and Genetics Research Complex, Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL, USA.

Xin Zhou (X)

Cancer and Genetics Research Complex, Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL, USA.

Lurong Zhang (L)

Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, No. 420, Fumalu Road, Jinan District, Fuzhou City, Fujian Province, People's Republic of China, 350014.

Ye Tian (Y)

Department of Radiation Oncology, the Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Institute of Radiotherapy & Oncology, Soochow University, Suzhou, Jiangsu, China.

Junqiang Chen (J)

Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, No. 420, Fumalu Road, Jinan District, Fuzhou City, Fujian Province, People's Republic of China, 350014. junqiangc@163.com.

Lengxi Fu (L)

Fujian Provincial Platform for Medical Laboratory Research of First Affiliated Hospital, Fuzhou, Fujian, People's Republic of China. fulengxi@126.com.
Central Laboratory, the First Affiliated Hospital of Fujian Medical University, Fuzhou City, Fujian Province, People's Republic of China, 350005. fulengxi@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH